Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06376851 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management

Study acronym: DECIDE
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 9 words Publications: details revised at 1 of 1 entry Show 1 more changeShow less
    • Publications: details revised at 1 of 1 entry
  2. Trial status: Enrolling by Invitation to Active, Not Recruitingv4
  3. Secondary endpoints: 9 to 11v3 See this version in full on ClinicalTrials.gov ↗
  4. Enrollment target: 10000 to 20000 Eligibility criteria expanded, about 61 words · Study arms: 4 to 6 · Study description shortened, about 1 wordv2 Show 3 more changesShow less
    • Eligibility criteria expanded, about 61 words
    • Study arms: 4 to 6
    • Study description shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The objective of HeartFlow's DECIDE Registry is to collect observational data about the management of patients before and after HeartFlow Artificial Intelligence-Quantitative Coronary Plaque Analysis (AI-QCPA).
Trial Details
NCT Number NCT06376851
Lead Sponsor HeartFlow, Inc.
Conditions Coronary Artery Disease
Enrollment 20,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov